使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Greetings, and welcome to the Align Technology, Inc. Second Quarter 2018 Earnings Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.
各位好,歡迎參加 Align Technology, Inc.2018 年第二季財報電話會議。(接線員指示) 提醒各位,本次會議將被錄音。
I would now like to turn the conference over to your host, Shirley Stacy, VP, Corporate and Investor Relations. Thank you. Please begin.
現在我想將會議交給本次會議主持人——企業與投資人關係副總裁 Shirley Stacy。謝謝。請開始。
Shirley Stacy - VP of Corporate Communications & IR
Shirley Stacy - VP of Corporate Communications & IR
Good afternoon, and thank you for joining us. I'm Shirley Stacy, Vice President of Corporate Communications and Investor Relations. Joining me for today's call is Joe Hogan, President and CEO; and John Morici, CFO.
各位下午好,感謝各位加入我們。我是 Shirley Stacy,企業傳播與投資人關係副總裁。今天與我一同出席電話會議的有總裁兼執行長 Joe Hogan,以及財務長 John Morici。
We issued second quarter 2018 financial results today via GlobeNewswire, which is available on our website at investor.aligntech.com. Today's conference call is being audio webcast and will be archived on our website for approximately 12 months. A telephone replay will be available today by approximately 5:30 p.m. Eastern time through 5:30 p.m. Eastern time on August 8. To access the telephone replay, domestic callers should dial (877) 660-6853 with conference number 13681104 followed by #. International callers should dial (201) 612-7415 with the same conference number.
我們今天透過 GlobeNewswire 發布了 2018 年第二季財務結果,可於我們網站 investor.aligntech.com 查閱。今天的電話會議將以音訊網路直播,並將在我們網站上保存約 12 個月。電話重播預計將於今日美東時間下午 5:30 左右提供,並持續至 8 月 8 日美東時間下午 5:30。如需收聽電話重播,美國境內來電者請撥打 (877) 660-6853,輸入會議編號 13681104 後按 #。國際來電者請撥打 (201) 612-7415,並使用相同的會議編號。
As a reminder, the information that the presenters discuss today will include forward-looking statements, including statements about Align's future events, product outlook and the expected financial results for the third quarter of 2018. These forward-looking statements are only predictions and involve risks and uncertainties that are set forth in more detail in our most recent periodic reports filed with the Securities and Exchange Commission. Actual results may vary significantly, and Align expressly assumes no obligation to update any forward-looking statement. We've posted historical financial statements, including the corresponding reconciliations and our second quarter conference call slides on our website under Quarterly Results. Please refer to these files for more detailed information.
提醒各位,今天簡報者所討論的資訊將包含前瞻性陳述,包括關於 Align 未來事件、產品展望,以及 2018 年第三季預期財務結果的陳述。這些前瞻性陳述僅為預測,並涉及風險與不確定性,相關內容在我們最近向美國證券交易委員會提交的定期報告中有更詳細的說明。實際結果可能有重大差異,Align 明確表示不承擔更新任何前瞻性陳述的義務。我們已在網站「季度結果」(Quarterly Results) 欄目下發布歷史財務報表(含相應調節表)以及第二季電話會議簡報投影片。如需更詳細資訊,請參閱這些檔案。
And with that, I'll turn the call over to Align Technology's President and CEO, Joe Hogan. Joe?
接下來,我將把電話會議交給 Align Technology 總裁兼執行長 Joe Hogan。Joe?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Thanks, Shirley. Good afternoon, and thanks for joining us. On our call today, I'll provide some highlights in the quarter and then briefly discuss the performance of our 2 operating segments: clear aligners and scanners. John will provide more detail on our financial results and discuss our outlook for the third quarter. Following that, I'll come back and summarize a few key points and open up the call to questions.
謝謝你,Shirley。各位下午好,感謝各位加入我們。在今天的電話會議中,我將先提供本季的一些重點,接著簡要說明我們兩個營運部門的表現:透明牙套與掃描器。John 將更詳細說明我們的財務結果,並討論第三季展望。之後我會回來總結幾個關鍵重點,並開放提問。
I'm pleased to report another better-than-expected quarter for Align. Our second quarter results reflect strong growth across our customer channels with record volume in all regions and almost every country market. Year-over-year, revenue growth of 37.5% was driven by continued momentum from Invisalign doctors and increased adoption of Invisalign treatment for teenage patients, which grew 42.1%. Q2 Invisalign volume growth of 30.5% year-over-year reflects increased utilization and expansion of our customer base, which was over 50,000 for the first time and included more than 5,000 new Invisalign-trained doctors. We also saw momentum from the iTero scanner and services business, which includes the continued roll-out of iTero scanners across Heartland Dental's supported offices as well as the first iTero scanner shipments to China.
我很高興報告 Align 再度交出一個優於預期的季度。我們第二季的結果反映出各客戶通路的強勁成長,在所有地區以及幾乎每個國家市場都創下歷史新高的出貨量。以年增率來看,營收成長 37.5%,主要由 Invisalign 醫師端的持續動能,以及青少年患者對 Invisalign 治療採用率提升所帶動;青少年業務成長 42.1%。第二季 Invisalign 出貨量年增 30.5%,反映使用率提升與客戶基礎擴大;客戶數首次超過 50,000 名,並包含超過 5,000 名新受訓的 Invisalign 醫師。我們也看到 iTero 掃描器與服務業務的動能,其中包括 iTero 掃描器在 Heartland Dental 所支援診所的持續導入,以及首批 iTero 掃描器出貨至中國。
Turning to specifics around our second quarter results. Let's start with results of our Americas region. For the Americas, Q2 was a good quarter with Invisalign volume -- case volume up 8.9% sequentially and 22.2% year-over-year, reflecting growth in both our orthodontic and also GP dentist channels. In Q2, we trained 1,795 new Invisalign doctors in the Americas region, of which 640 were in Latin America alone, where we trained more doctors in the first half of this year than we did all of last year. For the Americas region, year-over-year growth was led by orthodontist customers with another record quarter for North American ortho utilization at 16.4 cases per doctor. Q2 Invisalign utilization for North American GP dentists were also up year-over-year at 3.6 cases per doctor, reflecting continued expansion of the GP customer base, which represented over 20,000 GPs for the first time in a quarter.
接著說明第二季結果的具體細節。先從美洲地區的表現開始。在美洲地區,第二季表現良好,Invisalign 出貨量——病例量較前一季成長 8.9%,較去年同期成長 22.2%,反映我們在矯正專科與一般牙醫(GP)通路皆有成長。第二季我們在美洲地區訓練了 1,795 位新的 Invisalign 醫師,其中僅拉丁美洲就有 640 位;我們今年上半年在當地訓練的醫師數已超過去年全年。美洲地區的年增成長主要由矯正專科客戶帶動,北美矯正專科醫師使用率再創新高,達到每位醫師 16.4 例。北美一般牙醫(GP)在第二季的 Invisalign 使用率也較去年同期提升至每位醫師 3.6 例,反映 GP 客戶基礎持續擴大,單季首次超過 20,000 名 GP。
For international doctors, Q2 was another strong growth with Invisalign case volume up 14.9% sequentially and 45.4% year-over-year, reflecting strong Invisalign volume across the board, driven by both increased adoption as well as expansion of our customer base.
在國際醫師方面,第二季同樣維持強勁成長,Invisalign 病例量較前一季成長 14.9%,較去年同期成長 45.4%,反映各面向的 Invisalign 出貨量皆強勁,主要由採用率提升以及客戶基礎擴大所帶動。
For Q2, we're continuing to help expand the market for clear aligner treatment with approximately 1,650 newly trained doctors in EMEA. Year-over-year growth of Invisalign volume in EMEA was up 38%, with a record quarter in all geographies as well as the teenage segment, which was up 72% year-over-year. We also saw growth across our key expansion markets led by Central and Eastern Europe. In May, we announced the grand opening of our first Invisalign treatment planning facility in Europe located in Cologne, Germany. Until recently, Invisalign treatment planning for EMEA doctors was conducted in Align's treatment planning facility in Costa Rica. The Cologne facility will also serve as a training facility for Invisalign doctors with the German-speaking market, providing clinical education and support in local language. In September, we'll host a grand opening of our new treatment planning facility in Madrid, Spain, which will serve the Iberia market.
在第二季,我們持續協助擴大透明牙套治療市場,在 EMEA 地區約有 1,650 位新受訓醫師。EMEA 地區 Invisalign 出貨量年增 38%,各地理區域皆創下單季新高,青少年業務亦創新高,年增 72%。我們也看到關鍵擴張市場全面成長,其中以中東歐領先。5 月,我們宣布位於德國科隆的歐洲首座 Invisalign 治療規劃中心正式開幕。直到不久前,EMEA 醫師的 Invisalign 治療規劃仍是在 Align 位於哥斯大黎加的治療規劃中心進行。科隆中心也將作為德語市場 Invisalign 醫師的訓練基地,以當地語言提供臨床教育與支援。9 月,我們將在西班牙馬德里為新的治療規劃中心舉行開幕典禮,該中心將服務伊比利亞市場。
In APAC, Q2 Invisalign volumes were up 58.7% year-over-year, led by China, Japan, Australia and New Zealand. Our Q2 results reflect continued strong growth overall and especially from teen cases, which were up 74.3% year-over-year. China continues to drive the majority of growth in the Asia Pacific region, and we are increasingly leveraging digital and social media marketing programs. Japan also had a strong year-over-year Invisalign growth, driven primarily by orthodontists as well as continued uplift from iTero scanners. In addition, GP dentists channel in APAC was up 77.9% compared to last year. Q2 was an all-time high for Invisalign volume in our smaller expansion markets in Thailand and India, which are still very early in their development and adoption cycle.
在亞太地區(APAC),第二季 Invisalign 出貨量年增 58.7%,主要由中國、日本、澳洲與紐西蘭帶動。我們第二季的結果反映整體持續強勁成長,尤其是青少年病例,年增 74.3%。中國持續貢獻亞太地區大部分的成長,我們也日益運用數位與社群媒體行銷方案。日本的 Invisalign 年增也表現強勁,主要由矯正專科醫師帶動,並受惠於 iTero 掃描器的持續拉動效應。此外,亞太地區的一般牙醫(GP)通路較去年成長 77.9%。第二季在泰國與印度等較小的擴張市場,Invisalign 出貨量創下歷史新高;這些市場仍處於發展與採用週期的非常早期階段。
Now turning to the teen market. In Q2, 78,400 teenagers started treatment with Invisalign clear aligners, an increase of 13.6% sequentially and 42.1% year-over-year, driven by continued strong adoption across all major regions, led by North American orthodontists. Q2 was the seventh consecutive quarter that Invisalign teenage patient volumes grew faster than adults, reflecting a shift toward younger teens and tweens. For Q2, year-over-year Invisalign teen patient growth for North American orthos increased 30% and international doctors were up 73%.
接著談青少年市場。第二季共有 78,400 名青少年開始使用 Invisalign 透明牙套治療,較前一季成長 13.6%,較去年同期成長 42.1%,主要由各主要地區持續強勁的採用所帶動,其中以北美矯正專科醫師領先。第二季是 Invisalign 青少年患者量連續第七個季度成長速度快於成人,反映市場正轉向更年輕的青少年與學齡前後(tweens)族群。就第二季而言,北美矯正專科的 Invisalign 青少年患者年增 30%,國際醫師則年增 73%。
One of the key drivers behind our strong growth is continued product innovation. On July 1, we launched a new Invisalign Go product with a more user-friendly iTero digital chair-side experience and greater flexibility to treat a wider range of mild to moderate cases, such as crowded or gap teeth that require teeth straightening prior to restorative treatments. Invisalign Go also incorporates new data-driven clinical protocols for predictable tooth movement and automated case assessments, which will make it easier for dentists to tailor their treatments and plans to the individual needs of each patient. We're very excited about the potential for Invisalign Go to help accelerate adoption among GP dentists worldwide.
推動我們強勁成長的關鍵動能之一,是持續的產品創新。7月1日,我們推出全新的 Invisalign Go 產品,提供更易用的 iTero 數位椅旁體驗,並具備更高彈性,可治療更廣泛的輕度至中度病例,例如在進行修復治療前需要先矯正牙齒的牙齒擁擠或牙縫過大等情況。Invisalign Go 也納入新的數據驅動臨床流程,以實現可預測的牙齒移動與自動化病例評估,讓牙醫更容易依每位患者的個別需求量身打造治療與計畫。我們對 Invisalign Go 有助於加速全球一般牙醫(GP)採用的潛力感到非常振奮。
As we aim to create even greater preference for Invisalign treatment from doctors and consumers alike, especially in the teen market, a key factor is expanding clinically applicability of the Invisalign system in order to treat more complex cases. The launch of mandibular advancement feature last year has continued to ramp up and help drive adoption of Invisalign treatment among teenage patients in EMEA and APAC. Mandibular advancement feature is pending FDA approval in the U.S., and we continue to expect approval in the second half of this year.
當我們致力於讓醫師與消費者對 Invisalign 治療產生更高偏好、尤其是在青少年市場時,一個關鍵因素是擴大 Invisalign 系統的臨床適用性,以便治療更複雜的病例。去年推出的下顎前移(mandibular advancement)功能持續加速推進,並協助帶動 EMEA 與 APAC 地區青少年患者對 Invisalign 治療的採用。下顎前移功能在美國仍待 FDA 核准,我們仍預期將於今年下半年獲得核准。
On July 1, we began offering Invisalign First, designed specifically to address a broad range of younger patients' malocclusions, including shorter clinical crowns, management of eruption dentition and predictable dental arch expansion. While it's only been a few weeks, initial response to Invisalign First has been very positive, and excitement among top Invisalign doctors is rising. We're on a path to reach 1,000 Invisalign First cases across all regions in the first month alone.
7月1日,我們開始提供 Invisalign First,該產品專為解決更廣泛的年幼患者咬合不正而設計,包括較短的臨床牙冠、萌出期齒列的管理,以及可預測的牙弓擴張。雖然才過了幾週,Invisalign First 的初期反應非常正面,頂尖 Invisalign 醫師的熱度也在升高。我們正朝著在第一個月內於所有地區合計達到 1,000 例 Invisalign First 病例的目標邁進。
The $100 million investment we make each year in consumer marketing programs include TV, digital, social media, PR, event marketing, and more recently, our concierge service and Invisalign store pilot. Our goals are to make Invisalign brand a household name worldwide and to motivate consumers to seek Invisalign treatment through a doctor's office. In Q2, we continued to successfully leverage the Made to Move campaign we kicked off last year, which was our first fully integrated global consumer marketing campaign launched across all major markets. We also continued to build on regional programs like Teen and Mom campaign in North America and launched an entirely new initiative in APAC called Asian Smile in May.
我們每年投入 1 億美元於消費者行銷計畫,包括電視、數位、社群媒體、公關、活動行銷,以及近期的禮賓服務與 Invisalign 門市試點。我們的目標是讓 Invisalign 品牌成為全球家喻戶曉的名稱,並促使消費者透過醫師診所尋求 Invisalign 治療。在第二季,我們持續成功運用去年啟動的 Made to Move 活動,這是我們首個在所有主要市場推出的、完全整合式的全球消費者行銷活動。我們也持續深化區域性方案,例如北美的 Teen and Mom 活動,並於 5 月在 APAC 推出名為 Asian Smile 的全新倡議。
We have included the key indicators from our consumer marketing programs in the Q2 earnings slides posted on our website, so I won't go through them on this call. Needless to say, all metric for tracking consumer interest are up, with strong growth in Invisalign website visitors across APAC and opt-ins in the Americas region, which captures consumers who've taken action on our website and give us permission to contact them directly.
我們已將消費者行銷計畫的關鍵指標納入並發布於官網的第二季財報簡報中,因此我不會在本次電話會議逐一說明。毋庸置疑,用於追蹤消費者興趣的各項指標皆呈上升趨勢,其中 APAC 地區 Invisalign 網站訪客數強勁成長,而美洲地區的 opt-ins 也增加;opt-ins 指的是在我們網站上採取行動並授權我們可直接聯繫的消費者。
Our Smile Concierge program that we launched over a year ago is continuing to help more consumers start Invisalign treatment by shortening their research cycle and connecting them with an active Invisalign doctor. Year-to-date, we've scheduled over 30,000 Invisalign consultations in the U.S., which equates to connecting hundreds of consumers to Invisalign doctors every day. Concierge service is also equipping us with valuable consumer insights that help our doctors better engage with consumers and their practices and online. It's been very exciting to see how Invisalign doctors are working to reflect these insights and connect more effectively with the consumers that we send them every day. The Smile Concierge service is also expanding outside the U.S. with teams in Singapore, Brazil, Australia, and most recently, the U.K. And while it's still early, each of these countries are seeing great initial traction and helping more consumers become Invisalign patients.
我們在一年多前推出的 Smile Concierge(微笑禮賓)計畫,持續透過縮短消費者的研究決策週期並將其連結至活躍的 Invisalign 醫師,協助更多消費者開始 Invisalign 治療。截至今年迄今,我們已在美國安排超過 30,000 次 Invisalign 諮詢,這相當於每天將數百位消費者連結到 Invisalign 醫師。禮賓服務也為我們提供寶貴的消費者洞察,協助醫師在診所與線上更有效地與消費者互動。看到 Invisalign 醫師努力反映這些洞察,並更有效地與我們每天轉介給他們的消費者建立連結,令人非常振奮。Smile Concierge 服務也正擴展至美國以外地區,在新加坡、巴西、澳洲,以及最近的英國都已成立團隊。雖然仍在早期階段,但這些國家都展現了良好的初期動能,並協助更多消費者成為 Invisalign 患者。
Sole purpose of the Invisalign store is to connect new potential patients with Invisalign doctors in their offices by raising awareness of the Invisalign treatment and removing some common barriers for consumers to get started. Our experience with the stores continues to evolve and grow, and we are learning a lot from our consumers and participating doctors. To date, the Invisalign stores have contributed to a significant influx of consumer interest in the San Jose and San Francisco orthodontic marketplace. Over 8,000 consumers have visited our Align stores. The average participating doctor in the store network has received dozens of scanned consumers, with the top providers easily receiving over 150 consumers. Many doctors have said the Invisalign stores have far surpassed their top referral sources. Earlier this month, we opened a new -- 2 new Invisalign stores in Bethesda, Maryland and King of Prussia, Pennsylvania, and we're excited to see the impact these pilots will have on the participating Invisalign practices in the area. We look forward to continuing to learn more from these pilot locations, and we'll update you on our progress throughout the remainder of the year.
Invisalign 門市的唯一目的,是透過提升對 Invisalign 治療的認知並移除消費者開始治療時常見的一些障礙,將新的潛在患者引導至 Invisalign 醫師的診所。我們在門市方面的經驗持續演進與成長,並從消費者與參與的醫師身上學到很多。截至目前,Invisalign 門市已為聖荷西與舊金山的齒顎矯正市場帶來顯著的消費者興趣湧入。已有超過 8,000 名消費者造訪我們的 Align 門市。門市網絡中的平均參與醫師已收到數十位完成掃描的消費者,而頂尖提供者輕易就能收到超過 150 位消費者。許多醫師表示,Invisalign 門市的表現遠遠超過他們最主要的轉介來源。本月稍早,我們在馬里蘭州貝塞斯達(Bethesda)與賓夕法尼亞州普魯士王(King of Prussia)新開了兩家 Invisalign 門市,我們很期待這些試點對當地參與的 Invisalign 診所將帶來的影響。我們期待持續從這些試點據點學習,並在今年剩餘期間向各位更新我們的進展。
In Q2, iTero revenues were up 10.9% sequentially as we saw benefit from the launch of iTero Element 2 and Element Flex as well as the first commercial shipments of Element scanners in China. In April, we received China FDA approval to sell iTero Element in China, and today, we announced that we have received regulatory approval to manufacture iTero Element in our new manufacturing facility in Ziyang, China. Year-over-year, Q2 scanner revenues were up 60.9%, reflecting very strong growth across all regions and reflects the continued trend toward an end-to-end digital workflow starting with an iTero scanner on the front end. Not only do Invisalign doctors with an iTero scanner have notably higher utilization rates than non-iTero doctors, but it also enables greater efficiency between precision dentistry and higher overall customer experience and satisfaction.
第二季 iTero 營收較前一季成長 10.9%,我們受惠於 iTero Element 2 與 Element Flex 的推出,以及 Element 掃描儀在中國的首次商業出貨。4 月,我們取得中國 FDA 核准,可在中國銷售 iTero Element;而今天,我們宣布已取得監管核准,可在我們位於中國資陽的新製造工廠生產 iTero Element。以年對年來看,第二季掃描儀營收成長 60.9%,反映各地區非常強勁的成長,也反映出持續朝向端到端數位工作流程的趨勢,而該流程以前端的 iTero 掃描儀為起點。配備 iTero 掃描儀的 Invisalign 醫師不僅使用率明顯高於未使用 iTero 的醫師,iTero 也能在精準牙科之間帶來更高效率,並提升整體客戶體驗與滿意度。
Our Dental Service Organizations, or DSO partners, have recognized the strategic fit of the iTero scanners and are adopting the platform across their business. In Q2, Heartland Dental continued to roll out iTero scanners across their U.S.-supported locations and plan to have scanners in 90% of supported offices by the end of the year. Similarly, Aspen Dental will begin to roll out iTero scanners to their customer base over the next 2 quarters, beginning in Q3.
我們的牙科服務組織(Dental Service Organizations,DSO)合作夥伴已認可 iTero 掃描儀的策略契合度,並在其業務中採用該平台。在第二季,Heartland Dental 持續在其美國支援的據點推廣 iTero 掃描儀,並計畫在年底前讓 90% 的受支援診所配備掃描儀。同樣地,Aspen Dental 將在接下來兩個季度開始向其客戶群推廣 iTero 掃描儀,並自第三季起啟動。
Use of iTero scanners for Invisalign case submissions in place of PVS impression continues to grow and remains a positive catalyst for Invisalign utilization. For Q2, total Invisalign cases submitted with a digital scanner in the Americas increased to a record 69.3%, up from 67.3% in Q1. International scans increased 47.3%, up from 43.2% in Q1.
以 iTero 掃描儀提交 Invisalign 病例、取代 PVS 印模的使用持續成長,並仍是推動 Invisalign 使用量的正向催化因素。第二季,美洲地區以數位掃描儀提交的 Invisalign 病例占比提升至創新高的 69.3%,高於第一季的 67.3%。國際地區的掃描占比提升至 47.3%,高於第一季的 43.2%。
Finally, in a doctor-directed, at-home channel, Align is a third-party supplier to SmileDirectClub, or SDC. We manufacture a portion of SDC aligners, which are non-Invisalign clear aligners. For Q2, shipments to SDC were up sequentially and higher than expected. In April, SDC filed a complaint alleging that the launch and operation of Align's Invisalign store pilot program constitutes a breach of noncompete provisions applicable to the members of SDC Financial LLC, including Align. On June 29, 2018, the Chancery Court for Davidson County, Tennessee, denied SDC entities' request for a temporary injunction to prevent us from opening additional Invisalign stores. As you heard earlier, we will continue to open additional Invisalign stores as part of our pilot program designed to connect consumers interested in Invisalign treatment with Invisalign-trained doctors in their offices.
最後,在由醫師主導的居家通路中,Align 是 SmileDirectClub(SDC)的第三方供應商。我們生產部分 SDC 的牙套產品,這些屬於非 Invisalign 的透明牙套。第二季對 SDC 的出貨量較前一季增加,且高於預期。4 月,SDC 提出訴狀,主張 Align 的 Invisalign 門市試點計畫之推出與營運,構成對適用於 SDC Financial LLC 成員(包括 Align)之競業禁止條款的違反。2018 年 6 月 29 日,田納西州戴維森郡(Davidson County)衡平法院(Chancery Court)駁回 SDC 實體提出的臨時禁制令申請,該申請旨在阻止我們開設更多 Invisalign 門市。如同先前所述,我們將持續開設更多 Invisalign 門市,作為試點計畫的一部分,該計畫旨在將對 Invisalign 治療有興趣的消費者,與在其診所內受過 Invisalign 訓練的醫師連結起來。
We continue to dispute the allegations that we have breached our obligations to the SDC entities under applicable law and will oppose any -- with a vigorously defend ourselves in the arbitration proceedings currently scheduled for December 2018. As it relates to the SDC, we believed working with them was a way to influence and shape the evolving consumer market for clear aligners. Our objective was and still is to reach consumers who would not otherwise consider orthodontic treatment and connect them with Invisalign doctors in their offices. Our relationship with SDC has not worked out as expected. We have not been able to impact the decision-making process at SDC we had hoped, and transfer of the out-of-scope patients to an Invisalign doctor's office has not scaled as we had hoped. We do not anticipate renewing our supply agreement with SDC when it expires in 2019.
我們持續對於我們在適用法律下已違反對 SDC 各實體之義務的指控提出爭議,並將在目前排定於 2018 年 12 月的仲裁程序中反對任何主張——並將予以積極抗辯。就 SDC 而言,我們原本認為與其合作是影響並塑造透明牙套不斷演進之消費者市場的一種方式。我們的目標過去如此、現在亦然:觸及那些原本不會考慮接受齒顎矯正治療的消費者,並在其診所內將他們與 Invisalign 醫師連結起來。我們與 SDC 的合作關係未如預期發展。我們未能如所期望地影響 SDC 的決策流程,且將超出範圍的患者轉介至 Invisalign 醫師診所的作法,也未能如我們所希望地擴大規模。我們不預期在 2019 年到期時續約與 SDC 的供應協議。
With that, I'll now turn the call over to John.
接下來,我把電話交給 John。
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Thanks, Joe. Now for our Q2 financial results. Total company revenue for the second quarter was a record $490.3 million, up 12.2% from the prior quarter and up 37.5% from the corresponding quarter a year ago. Year-over-year revenue growth was favorable in all regions. Clear aligner revenue of $433.2 million was up 12.4% sequentially on higher-than-expected volume. Year-over-year clear aligner revenue growth of 35% reflected strong Invisalign shipment growth across all customer channels and geographies and increased Invisalign ASPs. Q2 Invisalign ASPs were up sequentially, approximately $5 from Q1 to $1,315, reflecting increased secondary revenue and favorable price mix, partially offset by unfavorable FX and sales promotions. On a year-over-year basis, Q2 Invisalign ASPs were up approximately $30, reflecting favorable FX, price increases and product mix, partially offset by sales promotions and deferrals related to additional aligners.
謝謝,Joe。接著說明我們第二季的財務結果。公司第二季總營收創下 4.903 億美元新高,較前一季成長 12.2%,較去年同期成長 37.5%。各地區的年增率皆表現良好。透明牙套營收為 4.332 億美元,因出貨量高於預期,較前一季成長 12.4%。透明牙套營收年增 35%,反映 Invisalign 在所有客戶通路與各地理區域的出貨強勁成長,以及 Invisalign 平均銷售單價(ASP)提高。第二季 Invisalign ASP 較前一季上升,約較第一季增加 5 美元至 1,315 美元,反映次要收入增加與有利的價格組合,但部分被不利的匯率影響與銷售促銷所抵銷。以年對年來看,第二季 Invisalign ASP 約增加 30 美元,反映有利的匯率、價格調漲與產品組合,但部分被銷售促銷以及與額外牙套相關的遞延所抵銷。
For the second quarter, total Invisalign shipments of 302,700 cases were up 11.2% sequentially and up 30.5% year-over-year, driven by growth across all regions. For Americas orthodontists, Q2 Invisalign case volume was up 9% sequentially and up 25% year-over-year. For Americas GP dentists, Invisalign case volume was up 8.6% sequentially and up 18.2% year-over-year. For international doctors, Invisalign case volume was up 14.9% sequentially and up 45.4% year-over-year.
第二季 Invisalign 總出貨量為 302,700 例,較前一季成長 11.2%,較去年同期成長 30.5%,成長動能來自所有地區。在美洲的矯正專科醫師方面,第二季 Invisalign 病例量較前一季成長 9%,較去年同期成長 25%。在美洲的一般牙醫(GP)方面,Invisalign 病例量較前一季成長 8.6%,較去年同期成長 18.2%。在國際醫師方面,Invisalign 病例量較前一季成長 14.9%,較去年同期成長 45.4%。
Our scanner and services revenue for the second quarter was $57 million, up 10.9% sequentially due to increased ASP benefiting from Element 2 and Element Flex product launches and the first Elements shipped into China. Year-over-year revenue was up 60.9% primarily due to higher volume, product mix and higher scanner ASPs.
第二季我們的掃描儀與服務營收為 5,700 萬美元,因 Element 2 與 Element Flex 產品上市,以及首批 Elements 出貨至中國帶動 ASP 提升,較前一季成長 10.9%。年對年營收成長 60.9%,主要由於出貨量增加、產品組合變化以及掃描儀 ASP 提高。
Moving on to gross margin. Second quarter overall gross margin was 74.6%, down 0.3 points sequentially and down 1.4 points year-over-year. Clear aligner gross margin for the second quarter was 76.5%, down 0.5 points sequentially primarily due to costs from the regional expansion of our manufacturing operation and increased aligners per case. Clear aligner gross margin was down 1.6 points year-over-year primarily due to regional expansion of our manufacturing activities and increased aligners per case, partially offset by higher worldwide ASPs. Scanner gross margin for the second quarter was 59.6%, up 0.4 points sequentially due to higher scanner ASPs, partially offset by higher production variances and freight costs. Scanner gross margins were up 2.9 points year-over-year primarily due to higher scanner ASPs along with increased manufacturing efficiencies.
接著談毛利率。第二季整體毛利率為 74.6%,較前一季下降 0.3 個百分點,較去年同期下降 1.4 個百分點。第二季透明牙套毛利率為 76.5%,較前一季下降 0.5 個百分點,主要由於製造營運的區域擴張所帶來的成本,以及每病例牙套數增加。透明牙套毛利率年對年下降 1.6 個百分點,主要由於製造活動的區域擴張與每病例牙套數增加,但部分被全球 ASP 提高所抵銷。第二季掃描儀毛利率為 59.6%,較前一季上升 0.4 個百分點,因掃描儀 ASP 提高,但部分被較高的生產差異與運費成本所抵銷。掃描儀毛利率年對年上升 2.9 個百分點,主要由於掃描儀 ASP 提高以及製造效率提升。
Q2 operating expenses were $242.9 million, up sequentially 6% and up 29.6% year-over-year. The increase in operating expenses reflects continued investment in our go-to-market activities, including higher advertising spending, geographic expansion as well as increased compensation related to expenses due to higher headcount.
第二季營業費用為 2.429 億美元,較前一季增加 6%,較去年同期增加 29.6%。營業費用增加反映我們持續投資於市場推進(go-to-market)活動,包括更高的廣告支出、地理擴張,以及因人員增加而帶來的薪酬相關費用上升。
Our second quarter operating income was $122.7 million, up 25% sequentially and up 46.8% year-over-year. Our second quarter operating margin was 25%, up 2.5 points sequentially and up 1.6 points year-over-year. The sequential increase in operating margin is primarily due to volume leverage and operating expense efficiencies. On a year-over-year basis, the increase in operating margin primarily reflects leveraged operating expenses on higher revenues from both clear aligner and scanner and services as well as favorable foreign exchange rates. With regards to the second quarter tax provision, our tax rate was 6.6%, which includes the impact of $16.6 million in excess tax benefits related to stock-based compensation. Second quarter diluted earnings per share was $1.30, up $0.13 sequentially and up $0.45 compared to the prior year.
第二季營業利益為 1.227 億美元,較前一季成長 25%,較去年同期成長 46.8%。第二季營業利益率為 25%,較前一季上升 2.5 個百分點,較去年同期上升 1.6 個百分點。營業利益率的季增主要來自規模效益(volume leverage)以及營業費用效率提升。以年對年來看,營業利益率提升主要反映在透明牙套以及掃描儀與服務兩大業務營收增加下,營業費用的槓桿效益,以及有利的外匯匯率。關於第二季所得稅費用,我們的有效稅率為 6.6%,其中包含與股票基礎薪酬相關的 1,660 萬美元超額稅務利益之影響。第二季稀釋後每股盈餘為 1.30 美元,較前一季增加 0.13 美元,較去年同期增加 0.45 美元。
Moving on to the balance sheet. As of the second quarter, cash, cash equivalents and marketable securities, including both short- and long-term investments were $720.7 million. This compared to $673 million at the end of Q1, an increase of approximately $47.7 million primarily due to increased collections and working capital improvements. Of our $720.7 million of cash, cash equivalent and marketable securities, $338.1 million was held in the U.S. and $382.6 million was held by our international entities. Q2 accounts receivable balance was $374.4 million, up approximately 3.6% sequentially. Our overall days sales outstanding, or DSOs, was 68 days, down 6 days sequentially and down 6 days from 74 days in Q2 last year. Our Q2 DSO is down sequentially as a result of improvements in both collections and AR aging. Capital expenditures for the second quarter were $57.7 million, primarily related to increased aligner capacity and facilities. Cash flow from operations for the second quarter was $139.8 million, up $29.3 million compared to the prior year. Free cash flow for the second quarter, defined as cash flow from operations less capital expenditures, amounted to $82.1 million. During the second quarter, we also announced a new $600 million stock buyback authorization. As of June 30, 2018, we have $100 million remaining under the April 2016 repurchase program that we expect to utilize during the remainder of 2018.
接著看資產負債表。截至第二季,現金、約當現金與有價證券(包含短期與長期投資)為 7.207 億美元。相較第一季末的 6.73 億美元,增加約 4,770 萬美元,主要由於收款增加與營運資金改善。在 7.207 億美元的現金、約當現金與有價證券中,3.381 億美元持有於美國,3.826 億美元由我們的國際實體持有。第二季應收帳款餘額為 3.744 億美元,較前一季約增加 3.6%。整體應收帳款週轉天數(DSO)為 68 天,較前一季減少 6 天,亦較去年第二季的 74 天減少 6 天。第二季 DSO 較前一季下降,係因收款與應收帳款帳齡(AR aging)均有所改善。第二季資本支出為 5,770 萬美元,主要用於提升牙套產能與相關設施。第二季營運活動現金流為 1.398 億美元,較去年同期增加 2,930 萬美元。第二季自由現金流(定義為營運活動現金流減資本支出)為 8,210 萬美元。第二季期間,我們亦宣布新增 6 億美元的庫藏股回購授權。截至 2018 年 6 月 30 日,我們在 2016 年 4 月回購計畫下尚餘 1 億美元額度,預期將於 2018 年剩餘期間內使用。
With that, let's turn to our Q3 outlook and the factors that inform our view, starting with the demand outlook. We expect our international business to grow on a sequential basis as APAC market is going into their strong teen season, offset somewhat by EMEA market going into their summer seasonality. For Americas, we expect North America to grow on strong teen demand, offset somewhat by seasonally slower adult season. LatAm will be flat on a sequential basis due to their summer holiday. We started selling iTero Element in China in Q2 of 2018. Additionally, Align has been effectively growing its iTero business in the North America DSO market. We expect a sequential increase in iTero units recognized as a result of these go-to-market activities. We continue to expect SmileDirectClub volume to be minimal in the third quarter.
接下來,我們談第三季展望以及支撐我們觀點的因素,先從需求展望開始。我們預期國際業務將在季對季基礎上成長,因亞太(APAC)市場進入青少年旺季,但部分會被歐洲、中東與非洲(EMEA)市場進入夏季季節性所抵銷。就美洲而言,我們預期北美將受惠於強勁的青少年需求而成長,但部分會被成人市場季節性較淡所抵銷。拉丁美洲(LatAm)因暑期假期,季對季預期持平。我們已於 2018 年第二季開始在中國銷售 iTero Element。此外,Align 亦在北美 DSO 市場有效擴展其 iTero 業務。由於這些市場推進活動,我們預期認列的 iTero 台數將季對季增加。我們仍預期 SmileDirectClub 在第三季的量將維持在最低水準。
With this as a backdrop, we expect the third quarter to shape up as follows: Invisalign case volume is expected to be in the range of 302,000 to 307,000 cases, up approximately 28% to 30% over the same period a year ago. We expect Q3 revenues to be in the range of $493 million to $503 million, an increase of approximately 28% to 31% year-over-year. We expect Q3 gross margin to be in the range of 74% to 74.4%, reflecting higher expenses as we regionalize our treatment planning and manufacturing operations, partially offset by higher ASPs. We expect Q3 operating expenses to be in the range of $245 million to $249 million, up on a sequential basis to reflect our continued investment in go-to-market activities. Q3 operating margin should be in the range of 24.2% to 24.9%. Our effective tax rate should be approximately 21%. We expect approximately $1.5 million equity loss related to our share of SmileDirectClub, and diluted shares outstanding should be approximately 81.6 million, exclusive of any share repurchases. Taken together, we expect our Q3 diluted earnings per share to be in the range of $1.13 to $1.18. In addition, as we continue our operational expansion efforts, we expect CapEx for Q3 to be approximately $60 million to $65 million and we expect depreciation and amortization to be $10 million to $11 million.
在此背景下,我們預期第三季表現如下:Invisalign 病例量預計介於 302,000 至 307,000 例之間,較去年同期約成長 28% 至 30%。我們預期第三季營收介於 4.93 億美元至 5.03 億美元之間,年增約 28% 至 31%。我們預期第三季毛利率介於 74% 至 74.4% 之間,反映我們在治療規劃與製造營運區域化過程中費用較高,部分由較高的平均售價(ASP)所抵銷。我們預期第三季營業費用介於 2.45 億美元至 2.49 億美元之間,較前一季增加,以反映我們持續投資於市場推廣(go-to-market)活動。第三季營業利益率應介於 24.2% 至 24.9% 之間。我們的有效稅率應約為 21%。我們預期與我們持有 SmileDirectClub 之持股份額相關的權益法損失約 150 萬美元,而稀釋後流通在外股數應約為 8,160 萬股,不含任何庫藏股回購。綜合以上,我們預期第三季稀釋後每股盈餘介於 1.13 美元至 1.18 美元之間。此外,隨著我們持續推動營運擴張,我們預期第三季資本支出(CapEx)約為 6,000 萬美元至 6,500 萬美元,並預期折舊與攤銷為 1,000 萬美元至 1,100 萬美元。
Now let me turn to our view of 2018. Based on the momentum in our business to date and our planned investments for the remainder of the year, we now anticipate 2018 total revenue growth rate to be above our long-term model and in the low to mid-30s. We expect Invisalign revenue and volume to be in the low 30s. Notwithstanding continued investments in our strategic growth drivers, we expect operating margin for the full year to be slightly up from 2017 operating margin of 24%.
接下來我談談我們對 2018 年的看法。基於目前為止業務動能以及我們對今年剩餘期間的投資規劃,我們現在預期 2018 年全年總營收成長率將高於我們的長期模型,落在 30% 出頭至 30% 中段。我們預期 Invisalign 營收與出貨量將在 30% 出頭。儘管我們仍持續投資於策略性成長驅動因素,我們預期全年營業利益率將較 2017 年 24% 的營業利益率略為上升。
With that, I'll turn it back over to Joe for final comments. Joe?
接下來,我把時間交還給 Joe 做最後評論。Joe?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Thanks, John, and thanks to those of you for joining our call today. 2018 is shaping up to be a very good year for Align, which reflects the continued execution of our 4 strategic goals and growth drivers that we focus on: driving international expansion; increasing orthodontist utilization of Invisalign, especially with teenagers; enabling GP dentists to treat or refer more Invisalign cases; and generating consumer demand for Invisalign treatment for millions of people worldwide. We are pleased to see continued momentum across all of our regions and customer channels and believe that the investments we are making will continue to drive our growth well above the underlying industry. There is still a lot of work to be done to fully optimize the enormous market potential, but we remain steadfast in our vision to bring clear aligner orthodontics to the masses through our partnership with Invisalign doctors. I look forward to updating you on our continued progress.
謝謝你,John,也謝謝各位今天加入我們的電話會議。2018 年看起來將是 Align 非常好的一年,這反映我們持續落實我們聚焦的 4 項策略目標與成長驅動因素:推動國際擴張;提高矯正專科醫師對 Invisalign 的使用率,尤其是在青少年族群;協助一般牙醫(GP)治療或轉介更多 Invisalign 病例;以及為全球數以百萬計的人創造對 Invisalign 治療的消費者需求。我們很高興看到在所有地區與客戶通路皆持續展現動能,並相信我們正在進行的投資將持續推動我們的成長,顯著高於產業基本面。要充分優化龐大的市場潛力仍有許多工作要做,但我們仍堅定秉持願景,透過與 Invisalign 醫師的合作,將透明牙套矯正帶給大眾。我期待向各位更新我們持續進展的情況。
With that, I'll turn it over to the operator, and we'll open the call up to your questions. Operator?
接下來,我把時間交給主持人,我們將開放各位提問。主持人?
Operator
Operator
(Operator Instructions) Our first question comes from the line of Jon Block with Stifel.
(主持人指示)我們的第一個問題來自 Stifel 的 Jon Block。
Jonathan David Block - MD & Senior Equity Research Analyst
Jonathan David Block - MD & Senior Equity Research Analyst
Two questions. Maybe the first one just on the guidance. Certainly, solid 3Q guidance but curious if you can talk about, at a high level, what that allows for, if anything, from the incremental competition. In other words, you guys always seem to be a bit conservative on the guide. Are you even leaving a bit more wiggle room due to the unknown uptick around suresmile and Clarity? And maybe just as a follow-on to that one, what, if anything, Joe, have you heard about these offerings over the past 2 months since the ortho show? And then I've got a follow-up.
兩個問題。第一個可能是關於財測指引。第三季指引當然相當穩健,但我想了解你們能否從較高層次談談,這是否已納入任何來自新增競爭的影響。換句話說,你們在指引上似乎一向偏保守。是否因為 suresmile 和 Clarity 相關的不確定性升高,而額外保留了更多緩衝空間?另外延伸問一下,Joe,過去兩個月自從矯正展(ortho show)之後,你對這些產品/方案有聽到什麼消息嗎?我還有一個追問。
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Jon, this is John. I'll start with the first part of your question. We guide like we always guide, taking the best information that we have, no change in terms of how we've taken this guidance. So we factor in many different factors into our forecast, and this is no different from a guidance standpoint.
Jon,我是 John。我先回答你問題的第一部分。我們的指引方式一如既往,依據我們掌握的最佳資訊來提供;在我們制定這次指引的方法上沒有任何改變。因此,我們在預測中會納入許多不同因素,這次在指引角度也沒有不同。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Jon, and from a competitive standpoint, there's nothing really different than what we saw from an AAO standpoint. I mean, obviously, you saw the Clarity product from Ormco that came out in Australia here recently. From what we see, it's -- there's -- again, it's just in line with other offerings that we see out there and we'll get -- I'll get, I think, a stronger beat on that in the future, but right now, I wouldn't say we've changed in any way our assessment of the competition that we saw at the AAO.
Jon,就競爭面而言,並沒有任何與我們在 AAO 上看到的情況有實質不同。我的意思是,很明顯你看到 Ormco 的 Clarity 產品最近在澳洲推出。就我們所見,它——同樣地——只是與我們在市場上看到的其他產品供給一致;未來我想我會對此有更明確的掌握,但就目前而言,我不會說我們對在 AAO 所見競爭態勢的評估有任何改變。
Jonathan David Block - MD & Senior Equity Research Analyst
Jonathan David Block - MD & Senior Equity Research Analyst
Okay, helpful. And then a follow-up. I'm going to push you a little bit on the gross margin trend. So I know the long term of 73% to 78% appears unchanged, but the 2Q Invisalign gross margin is 76.5%. In my model, it's one of the lowest in the past handful of years. And guys, maybe if you can talk about how that trends over the next 12 months. You talked about some of it being -- some of the deterioration being attributable to globalizing the supply chain. So do we think about, hey, as volume start to go through those sites in coming quarters, maybe we see the GM specific to Invisalign stabilize and maybe even possibly reverse that trend?
好的,很有幫助。接著追問。我想在毛利率趨勢上再多追問你們一些。我知道長期目標 73% 到 78% 看起來沒有改變,但第二季 Invisalign 毛利率是 76.5%。在我的模型中,這是過去幾年中較低的水準之一。各位能否談談未來 12 個月的走勢?你們提到部分下滑可歸因於供應鏈全球化。那麼我們是否可以這樣理解:隨著未來幾季量能開始在那些據點產出,Invisalign 的毛利率可能會趨於穩定,甚至有機會扭轉這個趨勢?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
That's right, Jon. As we're investing and globalizing -- and we think it's a long-term strategic importance to us, we'll see some of those investments. But as we add capacity and as we add production in those facilities, we'll see some improvement. And you also have to remember, too, we had a lot of -- from a mix standpoint, a lot of iTero in Q2. So the Q2 iTero affects us from a gross margin standpoint, but as you know, it's part of our long-term strategy and important for us from a growth standpoint.
沒錯,Jon。當我們投資並推動全球化——而我們認為這對我們具有長期策略重要性——我們會看到其中一些投資帶來的影響。但隨著我們在那些設施增加產能並提升產量,我們會看到一些改善。另外你也要記得,第二季在組合面上 iTero 的占比很高。因此,第二季 iTero 從毛利率角度會影響我們,但如你所知,這是我們長期策略的一部分,且從成長角度對我們很重要。
Operator
Operator
Our next question comes the line of Robert Jones with Goldman Sachs.
我們的下一個問題來自 Goldman Sachs 的 Robert Jones。
Robert Patrick Jones - VP
Robert Patrick Jones - VP
I guess just a few on the Aspen deal and the DSO opportunity more broadly. I guess, maybe, Joe or John, could you share how this deal came about? And more importantly, would you be willing to share anything around any economic structure around the arrangement if there's any kind of commitments or targets with Aspen? And then Joe, if I heard you correctly, I think you said that Heartland expects to have 90% of their practices with an iTero by the end of the year. Curious if you'd maybe be willing to share how the Invisalign growth or uptick has tracked at Heartland as we think about that as a proxy for Aspen.
我想問幾個關於 Aspen 交易以及更廣泛的 DSO 機會的問題。Joe 或 John,你們能否分享這筆交易是如何促成的?更重要的是,若安排中有任何經濟結構(例如承諾或目標),你們是否願意分享與 Aspen 之間相關的內容?另外 Joe,如果我沒聽錯的話,我想你說 Heartland 預期在年底前讓其 90% 的診所配備 iTero。我想了解,若把 Heartland 視為 Aspen 的一個參考,你們是否願意分享在 Heartland 那邊 Invisalign 的成長或提升幅度是如何追蹤/呈現的?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes. First, on the Aspen deal and the Heartland deal just from a high-level standpoint is I think you know we've had a really strong GP focus in this business. But it's difficult at times to have an individual just focus on accounts and to drive the kind of penetration in the marketplace that we want. We find that DSOs are great partners for us in the sense of their ability to be able to spread what we want to do with our digital workflow and with our aligners across their base. And so Heartland and Aspen both have been very open in the sense of working with us and front-loading their businesses with iTero that will allow them to -- give them a very strong position in clear aligners. And so that's -- it's just right [along] with our GP strategy and it allows us to be able to multiply that strategy across a number of different locations for the DSOs that really help us. We've been working with Heartland for a while in clear aligners, and their uptake of iTero scanners have been great. Our growth with Heartland has been -- really been terrific, and they've been able to translate it across their organization as well. We haven't shared a whole lot of numbers in the sense of how that's going, and we won't. That's how we want to handle that internally and how Heartland wants to handle that internally, too. But we're excited about the development, and we think it's a way for us to be able to -- it's a force multiplier for us in the sense of getting Align out there and getting it in the front of a lot of customers. And iTero is so critical from a digital workflow standpoint to make it really productive in a GP office as you do that.
是的。首先,從較高層次來看,關於 Aspen 交易與 Heartland 交易,我想你也知道,我們在這項業務上一直非常聚焦於一般牙醫(GP)。但有時要讓單一個人只專注於客戶帳戶,並推動我們希望在市場上達到的那種滲透率,是有難度的。我們發現,牙科服務組織(DSO)對我們而言是很好的合作夥伴,因為他們能夠把我們想做的數位工作流程以及我們的隱形矯正器(aligners)在其據點基礎上擴散推廣。因此,Heartland 與 Aspen 都非常願意與我們合作,並在其業務端前置導入 iTero,這將使他們——讓他們在透明隱形矯正器方面取得非常強的競爭位置。所以這——與我們的 GP 策略完全一致,也讓我們能把這個策略在多個據點上放大,透過真正能幫助我們的 DSO 來擴展。我們與 Heartland 在透明隱形矯正器方面合作已經有一段時間了,他們對 iTero 掃描儀的採用情況非常好。我們與 Heartland 的成長——確實非常出色,而且他們也能在其組織內部加以推廣落地。就進展如何而言,我們沒有分享太多數字,而且我們也不會。這是我們希望在內部處理的方式,Heartland 也希望在內部以同樣方式處理。但我們對這項發展感到興奮,我們認為這讓我們能夠——就把 Align 推向市場、讓更多客戶接觸到而言,這對我們是一種「倍增器」(force multiplier)。而從數位工作流程的角度來看,iTero 非常關鍵,能讓你在 GP 診所推動時真正提升生產力。
Robert Patrick Jones - VP
Robert Patrick Jones - VP
No, no. I appreciate that, Joe. And then if maybe I could just sneak one more in for John. On the 3Q EBIT margins, it looks a little maybe softer than expected following a relatively strong 2Q on the EBIT margin line. And so just was wondering if you could talk about some of the moving pieces. I think you talked about some of the spending -- areas of spend in your prepared remarks. So maybe just what informs that 3Q EBIT guide?
不,不。我理解,Joe。然後如果可以的話,我想再追加一個問題問 John。關於第三季 EBIT 利潤率,看起來在第二季 EBIT 利潤率相對強勁之後,第三季的指引可能略微偏弱、低於預期。所以想請你談談其中一些變動因素。我想你在事先準備的發言中提到了一些支出——支出領域。所以第三季 EBIT 指引主要是由哪些因素所驅動的?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
I mean, I think when we look at -- as was noted earlier, we are investing globally to try to -- as we regionalize some of our manufacturing and treatment planning. So there are some costs associated with that. We saw that in the second quarter. Some of that will continue into the third quarter and -- but we also see from an investment standpoint, from an operating expenditure standpoint, it's balanced. The high end of our guide is 24.9%, which is pretty consistent to what we saw in Q2.
我的意思是,我想當我們來看——如先前提到的,我們正在全球投資,試圖——在我們把部分製造與治療規劃區域化的同時。因此會有一些與此相關的成本。我們在第二季已經看到這點。其中一部分會延續到第三季——但同時我們也看到,從投資角度、從營運費用角度來看,這是平衡的。我們指引的高端是 24.9%,這與我們在第二季看到的水準相當一致。
Operator
Operator
Our next question comes from the line of Elizabeth Anderson with Evercore ISI.
我們的下一個問題來自 Evercore ISI 的 Elizabeth Anderson。
Kim Yoon - Associate
Kim Yoon - Associate
This is Suzie Yoon on for Elizabeth. It looks like total utilization was up nicely in the quarter. Could you just talk about some of the factors that drove the uptick in North America? And then a quick follow-up, given your findings from the stores so far, how are you thinking about the future store plans?
我是代替 Elizabeth 的 Suzie Yoon。看起來本季的總使用率提升得相當不錯。你能否談談推動北美使用率上升的一些因素?另外快速追問一下,根據你們目前從門市得到的觀察,你們如何看待未來的門市規劃?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
[As far as you know we've had in that] strong uptick internationally, APAC, EMEA but also North America. I'd say a lot of what -- you can see the growth from -- there's good growth from an orthodontic standpoint. A lot of that is a teen marketplace, and I think you've known from previous calls, Suzie, that we've focused a lot on teens. And that's a really important focus for us because that's a majority of what we see in the orthodontic marketplace is the teen piece. So you've seen further evidence of our ability to be able to go after that marketplace. We're excited about the teen first launch we put in place. It allows you to do a Phase I treatment, dental treatment on teens, and we have a good start like we talked about, almost 1,000 starts [here as we get off for the month]. So it just reflects the overall momentum that we continue to have that you've seen in other quarters, too. From a store standpoint, we just opened up 2 stores, 1 in Maryland and 1 in King of Prussia, Pennsylvania. We'll open up some more stores this year. We -- I think we're doing much better in the sense of preparing doctors of how to integrate those consumers with doctors. And also, we're learning a lot in the sense of how to communicate with patients with visualization tools and things in the store that excite them about the Invisalign treatment, and then we do the proper hand-off to the doctor's office to do that. So it's just another vector for growth for us and a continuation of our consumer interaction from an advertising standpoint and be able to monetize that with the doctor base.
[就你所知,我們在那方面]國際市場出現強勁上升,亞太(APAC)、歐洲中東非洲(EMEA),但北美也同樣如此。我會說,很多——你可以看到成長來自——從正畸(orthodontic)的角度來看有不錯的成長。其中很大一部分是青少年市場,而我想你從先前的電話會議也知道,Suzie,我們一直非常聚焦在青少年。這對我們是非常重要的重點,因為在正畸市場中,我們看到的多數需求就是青少年這一塊。所以你看到更多證據顯示我們有能力去切入並攻佔那個市場。我們對於推出的「teen first」上市方案感到興奮。它讓你能對青少年進行第一期(Phase I)治療、牙科治療;而且如我們所談到的,我們有一個很好的開局,幾乎有 1,000 個起始案例[在我們這個月剛開始時]。因此這反映了我們持續擁有的整體動能,你在其他季度也看到了。就門市而言,我們剛開了 2 家門市,1 家在馬里蘭州,1 家在賓夕法尼亞州的 King of Prussia。今年我們還會再開一些門市。我們——我認為我們在教導醫師如何把這些消費者與醫師端整合方面做得更好了。同時,我們也在學習如何透過視覺化工具以及門市內的一些方式與患者溝通,讓他們對 Invisalign 治療感到興奮,然後我們再把流程妥善交接到醫師診所去完成治療。所以這只是我們另一個成長向量,也是我們在廣告層面與消費者互動的延伸,並能透過醫師基礎將其變現。
Operator
Operator
Our next question comes from the line of Glen Santangelo with Deutsche Bank.
我們的下一個問題來自德意志銀行(Deutsche Bank)的 Glen Santangelo。
Glen Joseph Santangelo - MD & Research Analyst
Glen Joseph Santangelo - MD & Research Analyst
Joe, I just want to talk to you about North America in a little bit more detail. I mean, you have posted decent growth in that business. I think 22% case shipment growth this quarter. But over the last 6 quarters, it's trended pretty steadily in that 20% to 25% range. And I'm kind of curious to get your perspective, like what percentage of the docs in this region have already been trained? And I guess what I'm really trying to get at is what's really the key to sort of breaking out of that 20% to 25% range and accelerating that growth? Because it feels like we're seeing very strong growth on the ortho side. We're seeing strong growth in terms of teens, but that number seems to be flatlined in that 20% to 25% range. So what -- can you give us a little bit more color in terms of what's going on there?
Joe,我想更深入地談談北美。我的意思是,你們在這項業務上交出了不錯的成長。我想本季病例出貨量成長了 22%。但在過去 6 個季度,它相當穩定地維持在 20% 到 25% 的區間。我有點好奇想聽聽你的看法,例如這個地區的醫師大概有多少比例已經受過訓練?我想我真正想問的是,要如何才能突破 20% 到 25% 這個區間並加速成長的關鍵是什麼?因為感覺我們看到正畸端非常強勁的成長。我們也看到青少年方面的強勁成長,但那個數字似乎仍在 20% 到 25% 的區間內持平。所以——你能否多提供一些背景,說明那裡到底發生了什麼?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
We feel good about our North American marketplace. I mean, when you talk about North America, look at Canada and United States. And as you mentioned, and I'll reemphasize, the teen piece is going extremely well. We're doing well with GPs also on the lighter cases as we work through that. I'd say with that, with the steady state of that, when you start to look at our year-over-year comparisons, that's still a very strong performance from a North American standpoint. So what we're doing to continue to expand that, a new orthodontics [name], and of course, we train probably the majority of the orthodontists out there. But there's -- obviously, there's refreshes. There's new products. There's a lot of things we have to continue to reenergize that market with and educate the market as we change that. On the GP side, obviously, we just talked about the DSOs and that kind of opportunity for us, too. So -- and then we feel the stores really help with that consumer initiation and turning those consumers into patients. So overall, we have momentum in that marketplace. The third quarter is always a time where you see less of a GP marketplace and a strong orthodontic marketplace that kind of reverses in the fourth quarter. And so you'll see in our third quarter piece, we have a big number in there for teens on the ortho side to help that growth number.
我們對北美市場感到很有信心。我的意思是,談到北美,你看看加拿大和美國。而且如你提到的,我再強調一次,青少年這一塊進展非常順利。在我們逐步消化較輕病例的同時,我們在一般牙科醫師(GP)端也做得不錯。我會說,在這種穩定狀態下,當你開始看我們的年對年比較時,從北美的角度來看,這仍然是非常強勁的表現。因此,為了持續擴大這一點,我們有新的矯正醫師[名稱],當然,我們可能培訓了市面上大多數的矯正醫師。但也有——顯然,也會有更新換代。有新產品。有很多事情我們必須持續去重新活化這個市場,並在我們做出改變時教育市場。在GP端,顯然,我們剛剛談到DSO以及那類對我們而言的機會。所以——然後我們也覺得門市確實有助於消費者啟動,並把這些消費者轉化為病患。總體而言,我們在該市場有動能。第三季一向是你會看到GP市場較弱、而矯正市場較強的時期,到了第四季則會反轉。因此你會在我們第三季的部分看到,矯正端青少年有一個很大的數字,來支撐那個成長數字。
Glen Joseph Santangelo - MD & Research Analyst
Glen Joseph Santangelo - MD & Research Analyst
And maybe just one quick follow-up on the DSOs. What percentage of the North American market would you say is now represented by DSOs? And any other contracts you know above Heartland and Aspens sort of worth calling out? And what I'm really also trying to understand is, are these GPOs -- or DSOs, rather, are they just replacing the existing technology they have? Or are they using iTero to sort of augment maybe what they already have?
另外,關於DSO我可能再快速追問一個問題。你會說北美市場目前有多少比例是由DSO所代表?除了Heartland和Aspen之外,還有沒有其他合約值得特別提出?我真正也想理解的是,這些GPO——或者更正,是DSO——他們只是把既有的技術做替換嗎?還是他們使用iTero來補強他們目前已有的配置?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes. I think just to start with your last question, the iTero, it's new to their offices in the sense it's not an augmentation or replacement of equipment they currently have. It's more of a commitment to the DSOs for the -- for just the whole idea of digital dentistry. And obviously it uses a different workflow that you have inside GPs than you have on orthos. And we've been able to more and more make sure that we have that kind of workflow capability within iTero, and we can continue to work with that so we can be a great tool for GPs in that sense. The DSOs -- when you say what percentage of the market in North America, we normally quote 15% to 20%. That number kind of varies around depending on what you call a DSO and what you don't. So the upper number to use on that is 20%, and the other one is 15%. I hope I answered your question.
是的。我想先從你最後一個問題開始,iTero對他們的診所而言是新的,因為它不是在補強或替換他們目前已有的設備。它更像是DSO對——對於數位牙科這整個概念的一種承諾。而且很明顯,在GP端的內部流程,和在矯正端的流程是不同的。我們也越來越能確保iTero具備那種流程能力,並且我們可以持續在這方面努力,讓它在這個意義上成為GP很好的工具。至於DSO——你問北美市場的比例,我們通常引用15%到20%。這個數字會有些浮動,取決於你如何定義DSO、以及哪些不算。所以可用的上限是20%,另一個是15%。希望我有回答到你的問題。
Glen Joseph Santangelo - MD & Research Analyst
Glen Joseph Santangelo - MD & Research Analyst
Yes, that's fine.
是的,這樣就可以。
Operator
Operator
Our next question comes from the line of Steve Beuchaw with Morgan Stanley.
我們下一個問題來自Morgan Stanley的Steve Beuchaw。
Stephen Christopher Beuchaw - Equity Analyst
Stephen Christopher Beuchaw - Equity Analyst
The first question is on China. So when I think about the drivers for this year that are incremental, clearly, the China iTero launch is a big one. I wonder if you could dive in a little bit on how you think about the customer there. Maybe more specifically, are these people who had access to intraoral scanners and you're going through a swap process where you give them a better mousetrap? Or are these customers where they were really using PVS? Or is it somewhere in between?
第一個問題是關於中國。所以當我思考今年帶來增量的驅動因素時,很明顯,中國iTero的上市是一個很大的因素。我想知道你是否可以更深入談談你如何看待那邊的客戶。更具體地說,這些人是原本就能使用口內掃描儀、而你們正在進行一個換機流程,提供他們更好的解決方案嗎?還是這些客戶其實一直在使用PVS?或者是介於兩者之間?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Steve, it's amazing. I mean, it's all PVS. This is not replacing scanners that are over there. So it's not a swap. So if you would see our offices in China at any point in time, you'll just see rooms full of PVS boxes that would previously go to Mexico (inaudible) and we're seeing our -- the number of digital scans come out of China just start to skyrocket for us. John and I were going over that a couple of days ago on a trip. So it's a new foundation. It's just incredible -- I've been doing business in China now for over 20 years, and I'm always amazed at that country's ability to target a new technology and just integrate it so quickly into the workflow, just kind of -- it's the fastest uptake in new technology in any country I've ever seen in the last 20 years. I saw that in the medical equipment business, too. You have to train the marketplace. You have to get them ready. You have to be ready to service it well. There's a lot of just foundational infrastructure things you have to put in place there to be successful and not frustrate them. But once that's in place and know what to do, the uptake is amazing, and that's what we're seeing right now.
Steve,這真的很驚人。我的意思是,全部都是PVS。這不是在替換那邊既有的掃描儀。所以這不是換機。所以如果你在任何時間點去看我們在中國的診所,你只會看到一個房間又一個房間堆滿PVS盒子,這些以前會送到墨西哥(聽不清),而我們看到——來自中國的數位掃描數量開始對我們而言急速飆升。John和我幾天前出差時還在一起檢視這件事。所以這是一個新的基礎。這真的令人難以置信——我在中國做生意已經超過20年,我總是對這個國家鎖定新技術並且如此快速把它整合進工作流程的能力感到驚訝;某種程度上——這是我在過去20年看過任何國家中,新技術採用速度最快的。我在醫療設備業務中也看過同樣的情況。你必須訓練市場。你必須讓他們準備好。你必須準備好提供良好的服務。那裡有很多基礎建設層面的事情必須先到位,才能成功、也不會讓他們感到挫折。但一旦這些到位、也知道該怎麼做,採用速度就非常驚人,而這正是我們現在看到的。
Stephen Christopher Beuchaw - Equity Analyst
Stephen Christopher Beuchaw - Equity Analyst
That's what I was hoping for. And then just to follow up, I mean, you've given us between China and some of the DSO dynamics, reasons to think that the iTero trajectory this year remains really, really strong, certainly beating our numbers. Should we think about the first half as a reasonable barometer for iTero growth for the second half? Or are there other puts and takes that we ought to factor into the model?
這正是我所希望聽到的。接著再追問一下,我的意思是,你已經給了我們一些理由——包括中國以及部分DSO的動態——讓我們認為今年iTero的成長軌跡仍然會非常、非常強勁,肯定會超過我們的預估。我們是否應該把上半年視為下半年iTero成長的合理指標?或者還有其他利多利空因素是我們在模型中應該納入考量的?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
I don't know [if you want to take this] I think, Steve, these are -- you're right to call these out. I would call them anomalies in the sense of not -- I mean, there's going to be great uptake in China. This is the initial uptake in China. We expect more going forward. On the DSO side, I mean, Heartland and Aspen, 2 of the biggest DSOs going, so I wouldn't necessarily take a -- draw a line through this one and continue to draw it through the rest of the year, but we are having great success with iTero. You, as much as anybody, know how important that is from a standpoint of having an incredible foundation in place to be able to drive more Invisalign. And so you're seeing these big successes. We have little ones, too, but these are big penetration moves, and I wouldn't necessarily say that you just should take it times 2x as you go into the second half.
我不知道[你是否想接這題],我想,Steve,這些——你點出這些是對的。我會把它們稱為異常項,意思是並非——我的意思是,中國會有很好的採用。這是中國的初期採用。我們預期未來還會更多。在DSO端,我的意思是,Heartland和Aspen是目前規模最大的兩家DSO之一,所以我不一定會——把這一次畫一條線,然後把它一路延伸到今年剩下的時間,但我們在iTero方面確實取得很大成功。你和任何人一樣清楚,從建立一個令人驚艷的基礎、以推動更多Invisalign的角度來看,這有多重要。因此你會看到這些重大的成功。我們也有一些較小的成功,但這些是大型的滲透動作,而我不一定會說你應該在進入下半年時就把它直接乘以2倍。
Operator
Operator
Our next question comes from the line of Brandon Couillard with Jefferies.
我們的下一個問題來自 Jefferies 的 Brandon Couillard。
Brandon Couillard - Equity Analyst
Brandon Couillard - Equity Analyst
Joe, if you would, kind of discuss the decision to manufacture iTero systems in China, is that a cost play or a market access play? And would you expect over some period of time to actually shift more manufacturing to that location?
Joe,如果可以的話,請談談在中國製造 iTero 系統的決策:這是出於成本考量,還是市場准入的考量?另外,您是否預期在一段時間後,會把更多製造轉移到那個地點?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Hey, that's actually a really good question, okay? That's a market access play and it's -- again, I have some experience. I've seen that before. It's really important in the sense of how it's being done. And the Chinese government, those provincial governments have worked with us really well to make that work. And it's just so much easier to be able to address those Chinese regulations from a Chinese standpoint than it is, in this case, from an Israeli standpoint, too. So that's why we're doing it. From a cost standpoint, this is not a cost play. I'd say expect costs to be neutral. If they are a little worse or a little better, you won't see it in our numbers in any way. So I wouldn't put it in your model.
嘿,這其實是個非常好的問題,好嗎?這是市場准入的考量,而且——再說一次,我有一些相關經驗。我以前見過這種情況。就它如何被執行而言,這點非常重要。而中國政府以及各省級政府與我們合作得非常好,讓這件事得以推進。而且,從中國的角度去因應那些中國法規,要比在這個案例中從以色列的角度來做容易得多。所以這就是我們這麼做的原因。從成本角度來看,這不是一個成本策略。我會說成本預期是中性的。即便稍微差一點或好一點,你也不會在我們的數字中以任何方式看到它。所以我不會把它放進你的模型裡。
Brandon Couillard - Equity Analyst
Brandon Couillard - Equity Analyst
And a couple for John. First, any chance you could quantify the gross margin impact on the clear aligner business from the manufacturing capacity expansions? And then any pockets of inflation or material costs or freight or shipping costs that you're seeing in the business?
還有幾個問題給 John。第一,你是否能量化製造產能擴張對透明牙套業務毛利率的影響?第二,你們在業務中是否看到任何通膨的跡象,或材料成本、運費或運輸成本的上升?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Nothing from a freight or material cost that is of note. It simply comes down to, as we regionalize both from treatment planning as well as manufacturing going live in China from a manufacturing standpoint in Q4, there are start-up costs. You're adding that facility. You're training workers. You're getting that manufacturing up and running. And we saw some of that in Q2. We'll see some of that in Q3. And then as we grow and as we get more volume out of those facilities, you'll see [sub] normalize again. So it's short-term. It's something that we've expected. And then once we're fully up and running and we get the benefits of being local, faster to our customers, we reduce freight cost. There's a lot of other offsets that we see but we have to get that facility up and running, and that will be in Q4.
在運費或材料成本方面,沒有什麼值得特別一提的。主要就是,當我們在治療規劃以及製造端都進行區域化、並且在製造端於第四季在中國啟用時,會有啟動成本。你在新增那座廠房。你在訓練員工。你在讓製造產線上線並運轉。我們在第二季看到其中一些影響。第三季也會看到一些。然後隨著我們成長、以及從那些設施產出更多量,你會看到 [sub] 再次正常化。所以這是短期的。這是我們預期之中的事情。接著,一旦我們完全上線運轉,並獲得在地化的好處——更快服務客戶、降低運費成本——我們也看到很多其他的抵銷因素,但我們必須先把那座廠房建起來並運轉起來,而那會在第四季完成。
Operator
Operator
Our next question comes from the line of Erin Wright with Credit Suisse.
我們的下一個問題來自 Credit Suisse 的 Erin Wright。
Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst
Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst
On your retail store pilot, I understand it's still early days here, but you gave some preliminary metrics at your Investor Day as it relates to the sell-through traction with the retail stores and with the -- I guess, the majority of the scan, patient scheduling, appointments after visiting. I guess I'm curious, do you have an update on any of these metrics? And if there's a conversion rate at all that you could speak to into actual Invisalign customers.
關於你們的零售門市試點,我理解目前仍在早期階段,但你們在投資人日提供了一些初步指標,涉及零售門市的銷售轉化動能,以及——我想——大多數掃描、病患排程、到訪後的預約等。我想問的是,你們是否能更新這些指標的最新情況?以及是否有任何轉換率可以談談,例如轉為實際 Invisalign 客戶的比例。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Thanks for the question and thanks for the interest. I think at this point in time, we gave you as much as we wanted to give you at the investors meeting. We still call these pilot stores and they are. We're making a lot of iterations as we go through that, but we feel good about the progress. Yes, as we get more stores out there and we move this thing more firmly as our stores and not call them pilots and as we move into next year, we'll be more open with you in the sense of the close rates, number of patients going through. But as you know, as I mentioned and on our announcement, we have about 8,000 patients that have gone through those stores already. And then there's varying conversion rates, but again, not ready to share that yet.
謝謝你的提問,也謝謝你的關注。我想就目前而言,我們在投資人會議上已經提供了我們想提供的資訊。我們仍然稱這些為試點門市,而且確實如此。我們在推進過程中做了很多迭代,但我們對進展感到滿意。是的,隨著我們開出更多門市、並且更明確地把它們定位為我們的門市而不再稱為試點、以及進入明年之後,我們會在成交率、通過的病患數量等方面更願意對你們開放。但如你所知,正如我提到的、也在我們的公告中說過,我們大約已有 8,000 名病患已經走過這些門市流程。轉換率有高有低,但我們還沒準備好分享。
Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst
Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst
Okay, totally fair. The -- on the DSO relationships, I guess, can you speak to how the conversation in the sales cycle had evolved, I guess, at Aspen and potentially with other DSOs and the opportunity there? Is there any sort of new approach that you're taking from a DSO perspective in that sales process?
好的,完全合理。關於 DSO 的合作關係,我想請你談談在 Aspen 以及可能其他 DSO 的銷售週期中,對話是如何演變的,以及那裡的機會。從 DSO 的角度來看,在那個銷售流程中,你們是否採取了任何新的方法?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
We just -- we take a broad approach to both of them. They're -- these are very good businesses. They're extremely successful, what I call businesses, too, because they operate in a business sense. So we're able to, I think, communicate well in a broad sense what we can bring to the practice and how we can help to drive growth throughout. I mean, obviously, DSOs, one of the keys are going to be in store sales. And having -- being able to have an iTero inside that store and be able to drive more aligner sales, Invisalign sales through those is a big help. So it's just, we have organized within the business to be able to work with DSOs much better, bring the resources in place. And we put those things in place under Frank Quinn in the North American organization over the last 18 months. He's done a terrific job. So it's not just us. It's the DSOs reaching out for us, too. These are good partnerships that were well understood. And we're excited about both of them, and we feel they'll be successful.
我們只是——對兩者都採取廣泛的方式。它們——這些都是非常優質的企業。它們非常成功,我也把它們稱作企業,因為它們以商業化的方式運作。因此我認為我們能夠以更宏觀的方式良好溝通:我們能為診所帶來什麼,以及我們如何協助推動整體成長。我的意思是,顯然對 DSOs 而言,其中一個關鍵會是在門市端的銷售。而能在門市內配置 iTero,並透過這些門市推動更多牙套銷售、Invisalign 銷售,會是很大的助力。所以就是,我們在公司內部已經組織調整,以便更好地與 DSOs 合作,把資源配置到位。過去 18 個月,我們在北美組織由 Frank Quinn 之下把這些事情落實。他做得非常出色。所以不只是我們在推動。DSOs 也在主動聯繫我們。這些都是彼此充分理解的良好合作夥伴關係。我們對兩者都感到興奮,也相信它們會成功。
Operator
Operator
Our next question comes the line of Richard Newitter with Leerink Partners.
我們的下一個問題來自 Leerink Partners 的 Richard Newitter。
Richard S. Newitter - MD, Medical Supplies & Devices and Senior Analyst
Richard S. Newitter - MD, Medical Supplies & Devices and Senior Analyst
First one on just competition, Joe, is there anything -- since some of the competitors launched back in May, that you're hearing in terms of how they're approaching their and potentially your customer bases with respect to trialing or getting some initial kind of traction in the field? Or has it been relatively kind of quiet? And then with respect to the guidance question and competition, is there anything at all factored into your 2018 growth outlook, including the revised one? Any kind of impact from competition?
第一個問題關於競爭,Joe,自從一些競爭對手在 5 月推出之後,你是否聽到他們在現場如何切入、以及可能如何針對他們與你們的客戶群進行試用或取得初步動能?還是說整體相對安靜?另外,關於指引與競爭:你們對 2018 年成長展望(包括修訂後的版本)中,是否有納入任何競爭因素?是否有任何來自競爭的影響?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
I'd say from a competitive standpoint, what we see in the marketplace is kind of what you expect. I'd say it's a cautious approach from a competition standpoint. I'd call -- if you take a look at 3M, they more like slipstream into the marketplace behind their aligner -- behind their wires and brackets business and try a few -- to get a few uptakes. We'll be on the road this week in North America, just out talking to many customers, most of the MC staff. And the feedback that we get is they're being contacted and -- but there's nothing really that's different from what was the output from the AAO in that piece and it's -- so there is some interest and curiosity, I'd say, from a customer base. But there's not a momentum piece or anything that we're adjusting the business around right now.
我會說,從競爭的角度來看,我們在市場上看到的情況大致符合你的預期。我會說競爭方採取的是較為謹慎的方式。我會形容——如果你看看 3M,他們更像是沿著既有的路徑、依附在他們的牙套——依附在他們的鋼絲與托槽業務之後進入市場,並嘗試——爭取一些採用。我們本週會在北美出差,在外面與許多客戶、以及大多數 MC 團隊成員交流。我們得到的回饋是,他們確實有被聯繫——但並沒有什麼真正不同於 AAO 那次所呈現的情況,所以——我會說客戶群有一些興趣與好奇。但目前還沒有形成動能,或任何讓我們需要因此調整業務的事情。
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
And I would say, Rich, from -- as we guide and as we forecast, we're always looking at what's happening in the market, products that are coming, what's happening with competition. So that's in our way that we look at our guidance and what we expect to see coming. So when we look at our revenue that we talked here for 2018 to low to mid-30s, that is inclusive of what we see from a competitive standpoint.
Rich,我會說,從——就我們提供指引與進行預測而言,我們一直在觀察市場上正在發生的事情、即將推出的產品,以及競爭態勢的變化。因此,這就是我們看待指引以及我們預期未來走勢的方式。所以,當我們看我們在此談到的2018年營收、約落在30%出頭到30%中段的成長時,那是已經把我們從競爭角度所看到的情況納入其中。
Richard S. Newitter - MD, Medical Supplies & Devices and Senior Analyst
Richard S. Newitter - MD, Medical Supplies & Devices and Senior Analyst
Okay, great. And then maybe just one quick follow-up. You're still guiding to a mandibular advancement FDA approval in the back half of 2018. Anything that occurred intra-quarter to kind of give you the confidence to reiterate that time line? Any color there would be helpful.
好的,很棒。那再追問一個很快的問題。你們仍然指引下顎前移(mandibular advancement)在2018年下半年取得FDA核准。本季內是否發生了什麼事情,讓你們更有信心重申這個時間表?如果能補充一些說明會很有幫助。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
It's an old saying, "No news from the FDA is good news." So we're still looking at the fourth quarter for this year.
有句老話說:「FDA沒有消息就是好消息。」所以我們仍然預期會在今年第四季。
Operator
Operator
Our next question comes from the line of Steven Valiquette with Barclays.
下一個問題來自Barclays的Steven Valiquette。
Steven J. James Valiquette - Research Analyst
Steven J. James Valiquette - Research Analyst
I guess just for me, given that you mentioned that you do not plan to renew your current agreement with SmileDirectClub next year, just curious, kind of just thinking out loud about this, would you still consider partnering with other players in that direct market? Or is it more likely you'll just kind of abandon any partnerships and maybe just try your best on your own to just capture any volume in that direct market through your various initiatives?
我想就我這邊,鑑於你提到你們明年不打算續約與SmileDirectClub的現有協議,我只是好奇,稍微大聲思考一下,你們是否仍會考慮與直銷市場的其他業者合作?或者更可能的是,你們會放棄任何合作關係,改為靠自己、透過各項措施盡力在直銷市場中爭取任何可能的量?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes. I don't have any interest from a manufacturing standpoint of supporting other -- what we call direct-to-consumer kind of aligner companies. We're going to run our play in a sense of our stores and how we work with our doctor partners. We feel strongly that a doctor's office approach is a great approach to take given the seriousness of moving teeth, and that's the vector we're pursuing in this business. And so it would be kind of disingenuine (sic) [disingenuous] is after our agreement with SDC runs out that we go find another -- someone else to supply aligners, too, just we have no interest in that from a strategic standpoint at all.
是的。從製造的角度來看,我對於支持其他——我們所謂的直達消費者(direct-to-consumer)類型的隱形牙套公司——沒有任何興趣。我們會以我們的方式來推進,也就是我們的門市,以及我們如何與醫師合作夥伴一起運作。我們強烈認為,考量到牙齒移動的嚴肅性,採取「在醫師診所」的模式是一個很好的做法,而這就是我們在這項業務上所追求的方向。因此,在我們與SDC的協議到期後,如果我們再去找另一家——其他人來供應隱形牙套,那會有點不真誠(原文誤用disingenuine (sic) [disingenuous]),而且從策略角度我們完全沒有興趣。
Operator
Operator
Our next question comes from the line of Michael Ryskin with Bank of America Merrill Lynch.
下一個問題來自美國銀行美林(Bank of America Merrill Lynch)的Michael Ryskin。
Michael Leonidovich Ryskin - Associate
Michael Leonidovich Ryskin - Associate
Real quick one for you, for Joe, and then one for John. For the second half outlook and for the fiscal year, I noticed you bumped up the revenue guide incrementally. Is there anything there in terms of -- that you're seeing from the new products, whether it's mandibular advancement or internationally or from the new iTero launches or Invisalign First, that's giving you a little bit more confidence with how that started? Or is it more, let's call it, the legacy business that you're seeing stability in?
很快兩個問題,一個給Joe,另一個給John。關於下半年展望與全年,我注意到你們把營收指引小幅上調。這背後是否有任何因素——例如你們從新產品看到的情況,不論是下顎前移、國際市場、或新的iTero上市、或Invisalign First——讓你們對目前的起步更有信心?還是說,更多是你們看到既有(legacy)業務的穩定性?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Mike, this is John. I think it's a combination. I think we're seeing, as we've seen in the last couple of quarters here, great growth across our legacy business. We're driving great teenage growth. We have a lot of momentum internationally, and we're seeing that. But then as we've seen, we've seen great iTero volume as well, so the DSO business that we've talked about being able to have a release in China so that in the second quarter, we expect that to continue into the second half. So there's a lot of momentum given our existing business. But we have either new products on iTero with the various products that we have, Flex and iTero 2 and then also some of the expansion that we're doing in China and other places.
Mike,我是John。我認為是兩者的組合。我想我們看到的情況是,正如過去幾季一樣,我們的既有業務各面向都有很好的成長。我們在青少年市場帶動了很好的成長。我們在國際市場有很強的動能,我們也看到了。但同時,如同我們所見,我們的iTero出貨量也很強,因此我們談到的DSO業務,能夠在中國取得放行(release),所以在第二季我們預期這個趨勢會延續到下半年。因此,既有業務帶來了很大的動能。此外,我們在iTero上也有新產品,包含我們的各種產品,Flex和iTero 2,另外也包括我們在中國及其他地區所做的一些擴張。
Michael Leonidovich Ryskin - Associate
Michael Leonidovich Ryskin - Associate
Great. And then a quick follow-up on a previous question, specifically about iTero in China. You mentioned that right now -- or previously, it was all predominantly PVS. How do you -- how quickly do you see that market evolving? And can it get -- in 3, 5 years, can you get similar rates of digital submission as you get in North America or at least elsewhere internationally? Or how long of a time frame is it going to take to ramp that up?
很好。那再針對先前的一個問題快速追問,特別是關於中國的iTero。你提到目前——或先前——幾乎都以PVS為主。你們怎麼看這個市場的演進速度?在3到5年內,數位提交的比例能否達到像北美那樣的水準,或至少接近其他國際市場?或者需要多長時間才能把它拉升上來?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
I -- as I talked about in the last call, these ramp-up times in China will be faster than they were in the Western world. We know that. The intervening variable in that equation is we're signing up more and more doctors in China, not just orthodontists but GPs. And so those could entitle more PVS impressions, too. So if we look at the current kind of installed base of docs and who submits through that, I feel very confident you'll see this ramped up really dramatically in the next 2 to 3 years. But outside of that, we might have just other doctors who maybe not buy an iTero but still want to submit for -- that could come into the equation. It's just hard to project what that could be.
我——如同我在上次電話會議提到的,中國的爬坡時間會比西方世界更快。我們知道這一點。在那個等式中的中介變數是:我們在中國簽約的醫師越來越多,不只是矯正專科醫師,也包括一般牙醫(GPs)。因此,這也可能帶來更多PVS印模。所以如果我們看目前醫師的裝機基礎(installed base)以及誰透過該方式提交,我非常有信心在未來2到3年內你會看到這個比例大幅提升。但除此之外,我們可能還會有其他醫師,也許不買iTero,但仍想要提交——這也可能被納入考量。只是很難去預測那會是什麼樣的規模。
Michael Leonidovich Ryskin - Associate
Michael Leonidovich Ryskin - Associate
And then one really quick one. 5 points of FX tail in the first quarter, can you quantify? And the share was down -- smaller in 2Q, but how much was it?
再一個非常快的問題。第一季有5個百分點的匯率(FX)順風,你能量化一下嗎?而第二季的占比——比較小——那是多少?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Actually, 2Q was about 4%. So on a year-over-year basis, we saw a little bit less FX benefit on a year-over-year basis than the first quarter but still at 4%.
其實第二季大約是4%。所以以年對年來看,我們看到的匯率利益比第一季略少一些,但仍有4%。
Michael Leonidovich Ryskin - Associate
Michael Leonidovich Ryskin - Associate
And the same 1/3 flow through to the bottom line?
而且同樣有1/3流入到底線?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
That's correct. We saw actually about 2/3 flow through to the bottom line.
沒錯。我們實際上看到大約有2/3流入到底線。
Operator
Operator
Our next question comes from the line of Jeff Johnson with Robert W. Baird.
下一個問題來自Robert W. Baird的Jeff Johnson。
Jeffrey D. Johnson - Senior Research Analyst
Jeffrey D. Johnson - Senior Research Analyst
Maybe just a couple of cleanup questions here. Joe, I didn't hear you say anything about the 19% equity stake with SDC. Is there any change for that once you end the supply agreement at the end of '19?
這裡可能是幾個收尾問題。Joe,我沒有聽到你提到你們持有SDC 19%的股權。在你們於2019年底終止供應協議後,這部分會有任何變化嗎?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
I don't know honestly, Jeff. I'd say we still own that. We'll have to find a way to reconcile that, but that's -- after we get our operational conflict out of the way, I think that will be addressed.
老實說我不知道,Jeff。我會說我們仍然持有那部分。我們必須想辦法把這件事理順,但那是——在我們先把營運上的衝突處理掉之後,我想那部分就會被處理。
Jeffrey D. Johnson - Senior Research Analyst
Jeffrey D. Johnson - Senior Research Analyst
Okay, fair enough. And then on the store concept -- or the pilot store, sorry, how many more are you thinking about opening this year? And I guess, John, maybe you can walk us through. There's obviously expenses involved in opening those stores. I'd assume maybe that's a little bit of some of the EBIT questions that have been on the call today as well. But I also hear that you guys are getting full list price on those cases or at least very good pricing on those cases. So I would assume there's a breakeven here that's pretty quick on these stores. So any comments or kind of color you can provide on that would be helpful.
好的,合理。那關於門市概念——或試點門市,抱歉——你們今年還打算再開多少家?我想,John,也許你可以帶我們走一遍。開這些門市顯然會有費用。我猜這可能也解釋了今天電話會議上部分關於EBIT的問題。但我也聽到你們在那些案例上拿到的是完整牌價,或至少是非常好的定價。所以我會假設這些門市的損益兩平應該很快就能達到。因此,若你能對此提供任何評論或補充說明,會很有幫助。
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Yes, Jeff. This is John. Yes, you're right. Stores -- we've got 4 now. By the end of the year, we'll have 10 stores or so. It continues to -- we continue to find places that are very strategic to us. The right place to turn those consumers into patients through our doctors' offices. There's expenses related to start-up. There's also some targeted marketing that we do in the area. But don't think of it all as incremental. Think of it as we're spending money in certain places on some of the marketing and advertising. And instead of going as, maybe as broad, we can go a little bit more targeted to be able to try to get that consumer conversion. So when we look at the second half and what we've guided for the year, we've now said that we expect to be up in operating margin from 2014. So there's no flat anymore. So we -- with these investments that we're making, we still think that they're ultimately incremental to our business and a key part of our strategy.
是的,Jeff。我是John。是的,你說得對。門市——我們現在有4家。到今年年底,我們大約會有10家門市。這仍在持續——我們持續找到對我們而言非常具策略性的地點。在合適的地點,透過我們醫師的診所把這些消費者轉化為病患。啟動會有相關費用。我們也會在該區域做一些精準行銷。但不要把它全部都視為增量成本。把它想成我們在某些地點投入部分行銷與廣告費用。而不是做得可能那麼廣泛,我們可以更精準一些,以便嘗試提高消費者轉化。因此,當我們看下半年以及我們對全年所給出的指引時,我們現在已經表示,預期營業利益率將較2014年提升。所以不再是持平。因此我們——在進行這些投資的同時,仍然認為它們最終會為我們的業務帶來增量,並且是我們策略的關鍵部分。
Operator
Operator
Our next question comes from the line of John Kreger with William Blair.
下一個問題來自 William Blair 的 John Kreger。
John Charles Kreger - Partner & Healthcare Services Analyst
John Charles Kreger - Partner & Healthcare Services Analyst
Joe, I don't think you've mentioned the financing pilot. Can you just give us your latest thoughts on that and when you -- if you're considering taking it more broad, what the timing might be?
Joe,我想你還沒提到融資試點計畫。你能否談談你對此最新的看法,以及如果你考慮把它推廣到更廣的範圍,時程可能會是什麼時候?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
I'm turning you over to my expert on the financing objectives...
我把問題交給我們在融資目標方面的專家……
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Hey, John. This is John. So on finance, it's really moved from a pilot to -- it's fully released now. And what it is, is a tool that we have with our sales team as well as working with our doctors to be able to give patients options in terms of financing so they can do some things where they can look to come up with financing over a period of time. It's beneficial to the doctor. It's beneficial for the patients. Ultimately, we get paid faster. So there's a lot of wins, but really, what we're trying to do is make it easier for those end customers, those end patients to be able to come up with financing to be able to get them into treatment. And we think it's a benefit to everybody in this value chain to be able to get a higher conversion. So it's gone from pilot to full release, and we're actively working with doctors and potential patients to get them this -- get the understanding of this.
嗨,John。我是John。關於融資,它確實已經從試點——現在已全面推出。它是一個工具,我們的銷售團隊以及與我們合作的醫師可以用它,為病患提供融資選項,讓他們能在一段時間內安排融資。這對醫師有利。這對病患也有利。最終,我們能更快收到款項。所以有很多共贏,但我們真正想做的是,讓終端客戶、終端病患更容易取得融資,從而讓他們能進入治療。我們認為,為了提高轉化率,讓價值鏈上的每一方都能受益。因此,它已從試點走向全面推出,我們正積極與醫師及潛在病患合作,讓他們了解這項——了解這項安排。
John Charles Kreger - Partner & Healthcare Services Analyst
John Charles Kreger - Partner & Healthcare Services Analyst
Great. And then just one more follow-up, another DSO question. I think there's maybe 50 of size in the U.S. At least, that's my understanding. How many of those would you say you've got relationships with at this point?
很好。接著再追問一個,另一個關於 DSO 的問題。我認為美國大概有50家左右,至少這是我的理解。你會說目前你們與其中多少家建立了合作關係?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Well, I'd say we probably have contact with over 75% of them. I wouldn't say we have a relationship to the degree we have with Aspen and Heartland in that sense, John. So I mean, obviously, DSOs are on our list in the sense that [they'll] work with. And we put together an organization to do that. But right now, we're really focused on the agreements we've put in place, and we want to make sure that we really work and execute well on these.
嗯,我會說我們大概與其中超過75%有接觸。但我不會說我們的關係程度能像與 Aspen 和 Heartland 那樣,John。所以我的意思是,很明顯地,DSO 在我們的名單上,屬於我們會合作的對象。而我們也組建了一個組織來做這件事。但目前我們真正聚焦在已經簽訂的協議上,我們希望確保能把這些協議落實並執行到位。
Operator
Operator
Thank you. We have reached the end of our Q&A session. Allow me to hand the floor back over for closing remarks.
謝謝。我們的問答環節到此結束。請允許我把會議交回,進行結語。
Shirley Stacy - VP of Corporate Communications & IR
Shirley Stacy - VP of Corporate Communications & IR
Well, thank you everyone for joining us today. This concludes our conference call. If you have any follow-up questions, please contact our Investor Relations department. Have a great day.
好的,感謝各位今天加入我們。本次電話會議到此結束。如有任何後續問題,請聯絡我們的投資人關係部門。祝各位有美好的一天。
Operator
Operator
Thank you. This concludes today's conference. You may disconnect your lines at this time, and thank you for your participation.
謝謝。今天的會議到此結束。您現在可以掛線,並感謝您的參與。